Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
Jan B. Vermorken(University of Antwerp), Paul M. Clément(Universitair Ziekenhuis Leuven), Tim H. Brümmendorf(Heidelberg University), Jean‐Pierre Delord, Éva Remenár(National Institute of Oncology), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Thomas Gauler, Philippe Schafhausen(University Medical Center Hamburg-Eppendorf), Ulrich Keilholz(German Cancer Research Center), Ullrich Bethe(European Organisation for Research and Treatment of Cancer), John C. Krauss(University of Michigan), J. Erfán(Jósa András Múzeum), Christine Hicking(Merck KGaA, Darmstadt (Germany)), L. Iglesias(Research Institute Hospital 12 de Octubre), Frédéric Peyrade(Centre Hospitalier Universitaire de Nantes)
Cited by 95
Related Papers
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
|New England Journal of Medicine|2008|3.7k
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994